Checking heart arteries before valve replacement with a new scan
Tests a non-invasive heart scan against standard angiography in adults with severe aortic stenosis.
Plain-language title generated from the registry record
Registry title: Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
Key facts
- Where
- Innsbruck and Wels, AustriaSee the 2 sites
Where in Austria
- Medical University of InnsbruckInnsbruck, AustriaTaking people
- Department of Internal Medicine II, Cardiology and Intensive Care Medicine, Klinikum Wels-GrieskirchenWels, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University Innsbruck
- Trial code
- NCT07107568
- Record updated
- 7 October 2026
- Original description
The goal of this clinical trial is to determine whether a non-invasive coronary assessment strategy using photon-counting detector computed tomography (PCD-CT) is non-inferior to invasive coronary angiography (ICA) for evaluating coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.Read full original descriptionShow less
Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
The goal of this clinical trial is to determine whether a non-invasive coronary assessment strategy using photon-counting detector computed tomography (PCD-CT) is non-inferior to invasive coronary angiography (ICA) for evaluating coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.
Inclusion: Age ≥ 18 years; Severe aortic valve stenosis and indication for intervention according to current European Society of Cardiology (ESC) guidelines; TAVR candidate; Written informed consent.
Exclusion: Severe renal impairment with an estimated glomerular filtration rate of <30 mL/min/1.73 m²; Life expectancy <1 year due to other severe non-cardiac disease (e.g., malignancy); Cardiogenic shock at presentation (e.g., emergency indication for TAVR); Pregnancy.